LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial

Xu, Binghe; Yan, Min; Ma, Fenglian; Li, W.; Ouyang, Qi; Tong, Zhong Sheng; Teng, Yue; Wang, S.; Wang, Y.; Geng, Cuizhi; Luo, Tao; Zhong, Jian; Zhang, Q.; Liu, Q.; Zeng, Xiaoqin; Sun, Tao; Mo, Qi-Yan; Dong, F.; Wu, S.; Zhu, Xiaoqi

doi:10.1016/j.annonc.2022.08.014

Cited by 19 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Trastuzumab, pertuzumab combined with chemotherapy is regarded as a standard regimen in all settings for HER2+ breast cancer. 7 , 11 , 28 In addition, monoclonal antibody plus TKIs such as trastuzumab-lapatinib in early stage 29 and trastuzumab-pyrotinib in advanced stage 30 were also proved to be effective. A recent meta-analysis by Chen et al.…”

Section: Discussionmentioning

confidence: 99%

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis

Wang¹,

Xu²,

Wu³

et al. 2023

ESMO Open

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis

Wang¹,

Xu²,

Wu³

et al. 2023

ESMO Open

Self Cite

View full text Add to dashboard Cite

“…Median progression-free survival was increased from 10.4 months to 24.3 months. This corresponded to a hazard ratio of 0.41 (95% CI: 0.32 – 0.53) 56 .…”

Section: Interesting Research Data On Combination Therapies In Her2-p...mentioning

confidence: 97%

“…Vor diesem Hintergrund stellt sich die Frage, ob die Hinzunahme eines PI3K-Inhibitors bei Patientinnen mit einer HER2-positiven Erkrankung die Prognose verbessern kann. Diese Frage wurde in der PHILA-Studie untersucht 56 .…”

Section: Interessante Forschungsdaten Zu Kombinationstherapien Bei He...unclassified

“…Das mediane progressionsfreie Überleben konnte von 10,4 Monate auf 24,3 Monate verlängert werden. Dies entsprach einer Hazard Ratio von 0,41 (95%-KI: 0,32 – 0,53) 56 .…”

Section: Interessante Forschungsdaten Zu Kombinationstherapien Bei He...unclassified

“…In light of this, the question arises as to whether the addition of a PI3K inhibitor could improve the prognosis for patients with HER2-positive disease. This question was pursued in the PHILA study [56].…”

Section: Phila Studymentioning

confidence: 99%

See 2 more Smart Citations

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer

Lüftner¹,

Lux²,

Fehm

et al. 2023

Geburtshilfe Frauenheilkd

View full text Add to dashboard Cite

Large-scale study programs on CDK4/6 inhibitors, targeted therapies, and antibody–drug conjugates launched in recent years have yielded results from current studies which are now being published in journals and presented at international conferences. In this context, new results are available from the major CDK4/6 inhibitor studies. Also, an increasing amount of data is being published from large-scale genomic studies on efficacy and resistance mechanisms in patients treated with CDK4/6 inhibitors. These results now form the basis for further research plans to investigate combination therapies and treatment sequencing. Based on the latest published results, sacituzumab govitecan is now available as a second antibody–drug conjugate; this brings an advantage in terms of overall survival for patients with hormone receptor-positive (HRpos)/HER2-negative (HER2neg) breast cancer. In this review article, we summarize the latest developments and place them in context according to the current status of research.

show abstract

Advances in medical treatment of breast cancer in 2022

Zhai

et al. 2023

Cancer Innovation

View full text Add to dashboard Cite

Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, targeted therapy, endocrine therapy and immunotherapy. This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

show abstract

LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial

Cited by 19 publications

References 0 publications

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis

Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer

Advances in medical treatment of breast cancer in 2022

Contact Info

Product

Resources

About